What is the estimated market size for siRNA therapies in PV and related hematologic indications?
The press release excerpt you provided does not include a specific figure for the estimated market size of siRNA‑based therapies in polycythemia vera (PV) or the broader group of related hematologic indications. The information about market size, if it was disclosed, would appear elsewhere in the full release (typically in a section that discusses market opportunity or commercial potential), but it is not present in the text you shared.
Therefore, based on the news information supplied, we cannot give a concrete number for the market size of siRNA therapies in PV and related hematologic diseases. If you have access to the complete press release or additional documentation, that section should contain the estimate you’re looking for.
Other Questions About This News
How did the second‑quarter revenue and net loss compare to analyst consensus estimates?
What is the current cash balance and projected cash‑burn rate, and how many months of runway does the company have?
Are there any new partnership, licensing, or co‑development agreements that could impact future revenue streams?
What regulatory hurdles or FDA/EMA milestones could affect the timeline to approval for divesiran?
How might the Q2 results influence valuation multiples (e.g., EV/EBITDA, price‑to‑sales) for SLN compared to its peers?
How does the company’s R&D spend as a percentage of revenue compare to other siRNA peers such as Alnylam or Dicerna?
Are there any upcoming catalysts (e.g., conference presentations, data releases) that could drive the stock price in the near term?
When is the next data read‑out or regulatory filing for divesiran in polycythemia vera expected?
Did the company update its guidance for Q3 or full‑year 2025 earnings and cash flow?
What are the implications of the recent EHA data on the probability of success for divesiran’s development program?